165 related articles for article (PubMed ID: 8246023)
1. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
Anderson JE; Litzow MR; Appelbaum FR; Schoch G; Fisher LD; Buckner CD; Petersen FB; Crawford SW; Press OW; Sanders JE
J Clin Oncol; 1993 Dec; 11(12):2342-50. PubMed ID: 8246023
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.
Milpied N; Fielding AK; Pearce RM; Ernst P; Goldstone AH
J Clin Oncol; 1996 Apr; 14(4):1291-6. PubMed ID: 8648386
[TBL] [Abstract][Full Text] [Related]
3. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.
Jones RJ; Piantadosi S; Mann RB; Ambinder RF; Seifter EJ; Vriesendorp HM; Abeloff MD; Burns WH; May WS; Rowley SD
J Clin Oncol; 1990 Mar; 8(3):527-37. PubMed ID: 2307990
[TBL] [Abstract][Full Text] [Related]
4. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
5. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
Akpek G; Ambinder RF; Piantadosi S; Abrams RA; Brodsky RA; Vogelsang GB; Zahurak ML; Fuller D; Miller CB; Noga SJ; Fuchs E; Flinn IW; O'Donnell P; Seifter EJ; Mann RB; Jones RJ
J Clin Oncol; 2001 Dec; 19(23):4314-21. PubMed ID: 11731514
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
[TBL] [Abstract][Full Text] [Related]
10. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.
Lundberg JH; Hansen RM; Chitambar CR; Lawton CA; Gottlieb M; Anderson T; Ash RC
J Clin Oncol; 1991 Oct; 9(10):1848-59. PubMed ID: 1919635
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
13. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival.
Poen JC; Hoppe RT; Horning SJ
Int J Radiat Oncol Biol Phys; 1996 Aug; 36(1):3-12. PubMed ID: 8823253
[TBL] [Abstract][Full Text] [Related]
15. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
16. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.
Kusnierz-Glaz CR; Schlegel PG; Wong RM; Schriber JR; Chao NJ; Amylon MD; Hu WW; Negrin RS; Lee Y; Blume KG; Long GD
J Clin Oncol; 1997 Jan; 15(1):18-25. PubMed ID: 8996120
[TBL] [Abstract][Full Text] [Related]
17. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
18. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
[TBL] [Abstract][Full Text] [Related]
20. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z
J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
